KIF26A: A Potential Drug Target and Biomarker (G26153)

Target Name: KIF26A

NCBI ID: G26153

KIF26A

KIF26A: A Potential Drug Target and Biomarker

Introduction

Kidney injury is a significant public health issue worldwide, affecting millions of individuals and leading to significant economic costs. Chronic kidney disease (CKD) is a major risk factor for mortality and disability, and its progression to end-stage renal disease (ESRD) is Preventing and treating kidney damage and delaying disease progression have become hot research topics in the field of kidney disease. In recent years, with the application of endothelial growth factor (EGFR) receptor tyrosine kinase inhibitors (EGFR-TKIs), significant progress has been made in the treatment of renal cancer. However, the application of EGFR-TKIs in the treatment of renal injury remains challenging. As a new protein, KIF26A provides new ideas for studying kidney injury and kidney cancer.

Discovery and role of KIF26A

KIF26A is a transcription factor that mainly acts on renal tubular epithelial cells. Studies have found that KIF26A plays a key role in the proliferation, differentiation and apoptosis of renal tubular epithelial cells. Under normal circumstances, KIF26A controls gene expression by binding to DNA, thereby maintaining the homeostasis of renal tubular epithelial cells. However, during renal injury, the functional imbalance of KIF26A may lead to abnormal proliferation and differentiation of renal tubular epithelial cells, thereby triggering renal disease.

KIF26A and kidney injury

Kidney injury is a serious kidney disease that includes damage to the glomerular filtration membrane (glomerulus), damage to the tubular epithelial cells, and damage to the renal interstitium. Injury to renal tubular epithelial cells is one of the main pathogenesis mechanisms of renal injury. During the injury process of renal tubular epithelial cells, the functional imbalance of KIF26A may lead to abnormal proliferation and differentiation of renal tubular epithelial cells, thereby leading to renal tubular dysfunction and damage to renal tubular epithelial cells. In addition, KIF26A is also closely related to the apoptosis of renal tubular epithelial cells. Studies have shown that activation of KIF26A can lead to apoptosis of renal tubular epithelial cells, while inhibiting the function of KIF26A can extend the lifespan of renal tubular epithelial cells, thereby improving renal tubular function.

KIF26A and kidney cancer

Kidney cancer is a highly malignant tumor with high morbidity and mortality. The pathogenesis of kidney cancer is complex and involves multiple influences. KIF26A also plays an important role in kidney cancer. Studies have found that the expression level of KIF26A is positively correlated with the progression and invasion ability of renal cancer. In addition, KIF26A is also closely related to key processes such as growth, apoptosis and angiogenesis of renal cancer cells. Therefore, KIF26A is considered a potential target for renal cancer treatment.

Pharmacological significance of KIF26A

As a new protein, KIF26A has broad application prospects in the field of drug research and development. Currently, EGFR-TKIs (such as erlotinib, gemcitabine, etc.) have been widely used in the treatment of renal cancer, but the application of EGFR-TKIs in the treatment of renal injury is still challenging. As a new target, KIF26A provides new ideas for studying kidney injury and kidney cancer.

First, KIF26A can be used as a target for drug development to treat kidney damage and kidney cancer. Since the functional imbalance of KIF26A in renal tubular epithelial cells is closely related to the pathogenesis of kidney disease and cancer, using KIF26A as a drug target has significant clinical value.

Secondly, KIF26A can be used as a biomarker to evaluate kidney injury and kidney cancer. The clinical manifestations of kidney injury and cancer are complex, making it difficult to determine the severity of a patient's disease. KIF26A can be used as a biomarker to evaluate the severity of kidney damage and kidney cancer, providing a basis for disease diagnosis and treatment.

Third, KIF26A can be used as a target for drug development to treat kidney disease.

Protein Name: Kinesin Family Member 26A

Functions: Atypical kinesin that plays a key role in enteric neuron development. Acts by repressing a cell growth signaling pathway in the enteric nervous system development, possibly via its interaction with GRB2 that prevents GRB2-binding to SHC, thereby attenating the GDNF-Ret signaling (By similarity). Binds to microtubules but lacks microtubule-based motility due to the absence of ATPase activity (By similarity). Plays a critical role in cerebral cortical development. It probably acts as a microtubule stabilizer that regulates neurite growth and radial migration of cortical excitatory neurons (PubMed:36228617)

The "KIF26A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF26A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets